{"text_format":"3","workbook":"xls","n_sheets":3,"sheets":["Table1","Table2","Table3"],"not_rendered":{"external_links":1,"defined_names":3},"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"Table1","index":0,"n_rows":30,"n_cols":7,"rows_kept":30,"merged":[[0,0,0,6],[1,1,1,2],[1,3,1,4],[1,5,1,6],[2,1,2,2],[2,3,2,4],[2,5,2,6],[2,9,2,10],[29,0,29,6]],"flags":["formulas_cached_only"]}
["Table 1 Characteristics of patients who underwent MRCP and who showed elevated serum lipase values (>51 U/L) over one year (n = 91)"]
[null,"IPMN",null,"Cysts",null,"Non-cysts"]
[null,"(n = 20)",null,"(n = 15)",null,"(n = 56)"]
["Age (years)",77,"±9",73,"±12",69,"±12"]
["Male",11,"(55)",6,"(40)",21,"(38)"]
["Body mass index",{"v":23,"d":"23.0"},"±2.7",22.7,"±4.6",22.9,"±3.9"]
["Weight change in one year (kg)",0.4,"(-1.8-1.8)",0.2,"(-0.4-2.6)",0.6,"(-0.8-1.8)"]
["Weight loss ≥1 kg/year",6,"(30)",3,"(20)",10,"(18)"]
["Medications for epigastric discomfort",11,"(55)",5,"(33)",20,"(36)"]
["    H2-blockers",10,"(50)",2,"(13)",14,"(25)"]
["    Proton pump inhibitors",1,"(5)",2,"(13)",6,"(11)"]
["    Camostat mesilate",2,"(10)",2,"(13)",5,"(9)"]
["Present symptoms",1,"(5)",1,"(7)",5,"(9)"]
["History of acute pancreatitis",0,"(0)",0,"(0)",0,"(0)"]
["History of chronic pancreatitis",1,"(5)",2,"(13)",2,"(4)"]
["Parents' with pancreatic carcinoma",1,"(5)",0,"(0)",3,"(5)"]
["Ever smoker",3,"(15)",4,"(27)",10,"(18)"]
["Ever drinker",4,"(20)",2,"(13)",12,"(21)"]
["Glucose-lowering drugs",2,"(10)",4,"(27)",14,"(25)"]
["Blood pressure-lowering drugs",10,"(50)",11,"(73)",28,"(50)"]
["Lipid-lowering durgs",7,"(35)",4,"(27)",20,"(36)"]
["Systolic blood pressure (mmHg)",{"v":131.8,"d":"132"},"±15",131,"±16",128,"±16"]
["Diastolic blood pressure (mmHg)",{"v":74.4,"d":"74"},"±12",75,"±10",{"v":71.1,"d":"71"},"±13"]
["Alkaline phosphatase (U/L)",216,"±54",259,"±72",227,"±90"]
["Gamma-glutamyl transpeptidase (U/L)",21,"(16-31)",24,"(22-38)",24,"(17-41)"]
["Estimated glomerular filtration rate (mL/min/1.73m2)",70,"(58-78)",64,"(53-87)",67,"(56-76)"]
["Proteinuria",1,"(5)",1,"(7)",7,"(13)"]
["Examined by gastroscopy",14,"(70)",12,"(80)",27,"(48)"]
["    Positive for Helicobacter pylori",2,"(14)",0,"(0)",5,"(19)"]
["Data are means ± standard deviation, median (interquartile range) or n (%). Present symptoms include epigastric discomfort, nausea, back pain, appetite loss, and diarrhea. MRCP, magnetic resonance colangio-pancreatography; IPMN, intraductal papillary mucinous neoplasm; cysts, pancreatic cystic lesions other than IPMN; H2-blockers, histamine H2-receptor antagonists."]

{"sheet":"Table2","index":1,"n_rows":23,"n_cols":11,"rows_kept":23,"merged":[[0,0,0,10],[1,1,1,2],[1,3,1,4],[1,5,1,6],[2,3,2,4],[2,5,2,6],[2,7,2,8],[2,9,2,10],[22,0,22,10]],"flags":["formulas_cached_only"]}
["Table 2 Prevalence of IPMN and other pancreatic cystic lesions according to the levels of serum lipase, weight loss, and taking H2-blockers (n = 91)"]
[null,"IPMN",null,"Cysts",null,"Non-cysts",null,"Adjusted ORa","(95% CI)","Adjusted ORa","(95% CI)"]
[{"$nulls":7},"IPMN vs. Non-cysts",null,"Cysts vs. Non-cysts"]
["Total",20,"(22.0)",15,"(16.5)",56,"(61.5)"]
["Serum lipase levels"]
["    Borderline hyperlipasemia (<60 U/l)",6,"(17.1)",3,"(8.6)",26,"(74.3)",1,"(reference)",1,"(reference)"]
["    Mild hyperlipasemia (60-79 U/L)",10,"(35.7)",5,"(17.9)",13,"(46.4)",5.2,"(1.2-22.4)",3.7,"0.7-19.3)"]
["    Moderate hyperlipasemia (≥80 U/L)",4,"(14.3)",7,"(25.0)",17,"(60.7)",{"v":1,"d":"1.0"},"(0.2-5.2)",3.7,"(0.8-17.6)"]
["Weight loss ≥1 kg/year"]
["    No",14,"(19.4)",12,"(16.7)",46,"(63.9)",1,"(reference)",1,"(reference)"]
["    Yes",6,"(31.6)",3,"(15.8)",10,"(52.6)",{"v":5.86,"d":"5.9"},"(1.3-27.2)",1.5,"(0.3-7.2)"]
["Mild hyperlipasemia and weight loss ≥1 kg/year"]
["    None",7,"(13.7)",8,"(15.7)",36,"(70.6)",1,"(reference)",1,"(reference)"]
["    Either",10,"(30.3)",6,"(18.2)",17,"(51.5)",5.1,"(1.3-19.4)",1.9,"(0.5-6.7)"]
["    Both",3,"(42.9)",1,"(14.3)",3,"(42.9)",16.5,"(1.3-210.6)",3.4,"(0.2-48.4)"]
["Taking H2-blockers"]
["    No",10,"(15.4)",13,"(20.0)",42,"(64.6)",1,"(reference)",1,"(reference)"]
["    Yes",10,"(38.5)",2,"(7.7)",14,"(53.9)",3.6,"(1.0-12.4)",0.4,"(0.1-2.0)"]
["Mild hyperlipasemia and taking H2-blockers"]
["    None",6,"(13.3)",8,"(17.8)",31,"(68.9)",1,"(reference)",1,"(reference)"]
["    Either",8,"(21.1)",7,"(18.4)",23,"(60.5)",2.5,"(0.6-9.3)",1.2,"(0.4-3.8)"]
["    Both",6,"(75.0)",0,"(0)",2,"(25.0)",21.2,"(2.2-204.7)","_","_"]
["IPMN, intraductal papillary mucinous neoplasm; cysts, pancreatic cystic lesions other than IPMN; H2-blockers, histamine H2-receptor antagonists; eGFR, estimated glomerular filtration rate; OR, odds ratio; CI, confidence interval. Patients who showed elevated serum lipase values (>51 U/L) during one year were included. \naAdjusted for age groups in decade, sex, and eGFR levels. Bold style represents statistically significant ORs."]

{"sheet":"Table3","index":2,"n_rows":16,"n_cols":7,"rows_kept":16,"merged":[[0,0,0,6],[1,1,1,2],[1,3,1,4],[1,5,1,6],[2,1,2,2],[2,3,2,4],[2,5,2,6],[2,9,2,10],[4,5,4,6],[5,5,5,6],[6,5,6,6],[7,5,7,6],[8,5,8,6],[15,0,15,6]],"flags":["formulas_cached_only"]}
["Table 3 Characteristics of IPMN and other pancreatic cystic lesions assessed by MRCP"]
[null,"IPMN",null,"Cysts",null,"Non-cysts"]
[null,"n = 20",null,"n = 15",null,"n = 56"]
["Location"]
["    Head",13,"(65)",6,"(40)","NA"]
["    Body",5,"(25)",7,"(47)","NA"]
["    Tail",8,"(40)",7,"(47)","NA"]
["Size of the largest tumor/cyst (mm)",9,"(6-16)",3,"(2-7)","NA"]
["Multifocality",9,"(45)",4,"(27)","NA"]
["Main pancreatic duct dilatation",2,"(10)",0,"(0)",1,"(2)"]
["Pancreatic degeneration",5,"(25)",6,"(40)",12,"(21)"]
["Liver cysts",10,"(50)",1,"(7)",18,"(32)"]
["Renal cysts",6,"(30)",5,"(33)",18,"(32)"]
["Gallstones",2,"(10)",2,"(13)",11,"(20)"]
["Adenomyomatosis",4,"(20)",0,"(0)",9,"(16)"]
["MRCP, magnetic resonance colangio-pancreatography; IPMN, intraductal papillary mucinous neoplasm; cysts, pancreatic cystic lesions other than IPMN; NA, not applicable. "]